MANTECH Publications
International Journal of Drug Formulation, Development & Research
Volume 3, Issue 2, July-December, 2025

Biopharmaceutical Considerations in Oral Drug Formulation: Enhancing Solubility and Permeability

Dr. Neha Sharma
Assistant Professor,
Department of Pharmaceutics,
Delhi Institute of Pharmaceutical Sciences and Research (Dipsar),
Email ID: *nehasharma.pharma@rediffmail.com*

ABSTRACT

Oral drug delivery remains the most preferred and convenient route of administration. However, challenges such as poor solubility, low permeability, and enzymatic degradation limit therapeutic efficacy. This paper explores biopharmaceutical considerations in oral drug formulation, focusing on solubility enhancement, permeability optimization, and stability improvement. Strategies such as prodrug design, lipid-based formulations, and solid dispersions are critically reviewed. Additionally, in vitro and in vivo evaluation methods are discussed to assess bioavailability and pharmacokinetics. Emphasis is placed on integrating formulation strategies with biopharmaceutical classification system (bcs) frameworks to predict drug absorption and therapeutic performance. The paper also highlights regulatory and quality aspects essential for successful formulation development.

Keywords: *oral drug delivery, solubility enhancement, permeability, biopharmaceutical classification, formulation strategies*

Introduction

the oral route remains the most preferred and convenient method for drug administration due to its ease of use, cost-effectiveness, and patient compliance. However, successful oral delivery is often hindered by poor aqueous solubility and low intestinal permeability, resulting in inadequate absorption and therapeutic failure. Biopharmaceutical considerations

play a vital role in bridging the gap between a drug's physicochemical properties and its pharmacokinetic performance.

The drug's journey from the dosage form to systemic circulation involves several barriers, including dissolution in gastrointestinal fluids, permeation through the intestinal epithelium, and pre-systemic metabolism. A comprehensive understanding of these barriers and strategies to overcome them is essential for optimizing oral drug formulations. This paper aims to present an integrated overview of the biopharmaceutical factors governing solubility and permeability, recent formulation advancements, and practical approaches to enhance oral bioavailability.

LITERATURE REVIEW

Overview of biopharmaceutical principles

Biopharmaceutics is the study of the relationship between the physical, chemical, and biological properties of drugs and their dosage forms on the rate and extent of drug absorption. It emphasizes how formulation variables and physicochemical properties affect drug performance. The biopharmaceutical classification system (bcs), introduced by amidon et al., categorizes drugs based on their solubility and intestinal permeability into four classes.

Biopharmaceutical classification system (BCS)

Table 1: biopharmaceutical classification system (BCS) and its formulation implications

Bcs class	Solubility	Permeability	Formulation challenge
I	High	High	Minimal issues; dissolution is rapid
Ii	Low	High	Solubility enhancement required
Iii	High	Low	Permeability enhancement required
Iv	Low	Low	Dual challenge; complex formulation strategies

This classification aids formulators in identifying appropriate strategies to improve oral bioavailability. For example, class ii drugs benefit from solubility enhancement approaches, while class iii drugs require permeability modulation or transporter targeting.

Bcs class	Solubility	Permeability	Examples of drugs	Formulation approach
Class i	High	High	Metoprolol, propranolol	Conventional tablets or capsules
Class ii	Low	High	Ketoconazole, ibuprofen	Solubility enhancement using solid dispersions, nanoparticles
Class iii	High	Low	Cimetidine, acyclovir	Permeability enhancement using absorption promoters or prodrugs
Class iv	Low	Low	Hydrochlorothiazide, furosemide	Complex multi-strategy formulations (lipid-based or nanocarriers)

Role of solubility and permeability solubility refers to the maximum concentration of a drug that can dissolve in a solvent at a specific temperature and ph. It determines the rate of dissolution, which is a prerequisite for absorption. Permeability, on the other hand, describes the ability of the drug to cross biological membranes. Both parameters are crucial for achieving sufficient plasma concentrations after oral administration. Drugs with poor solubility often exhibit variable absorption, while those with low permeability face restricted transport across intestinal barriers.

Challenges in oral drug formulation

The development of an effective oral dosage form involves addressing multiple biopharmaceutical and physicochemical challenges that directly influence drug absorption, stability, and overall therapeutic performance. Although the oral route remains the most patient-friendly mode of administration, achieving consistent and predictable bioavailability is often complicated by a combination of poor solubility, limited permeability, physiological variability, and formulation instability. Each of these challenges requires careful consideration during the design and optimization of the drug product.

1. Poor aqueous solubility

Poor solubility is one of the most prevalent and critical hurdles in oral drug formulation. The solubility of a drug in aqueous gastrointestinal fluids governs its dissolution rate, which in

turn determines the concentration available for absorption. Drugs belonging to biopharmaceutical classification system (bcs) class ii and iv categories are particularly affected by low solubility, often leading to erratic absorption profiles and suboptimal therapeutic response.

Modern drug discovery trends, such as combinatorial chemistry and high-throughput screening, tend to generate molecules with high lipophilicity (high log p values), large molecular weight, and multiple aromatic rings — all of which contribute to poor water solubility. For example, approximately **40% of currently marketed drugs** and nearly **70% of new chemical entities (nces)** exhibit low aqueous solubility.

From a formulation perspective, this limitation results in **slow dissolution rates**, **dose-dependent absorption**, and **poor bioavailability**, especially when the drug fails to reach the required solubilized concentration at the absorption site. Overcoming this issue often involves the application of advanced solubilization techniques, such as micronization, amorphization, solid dispersion technology, use of surfactants, or lipid-based delivery systems. However, these approaches may also introduce challenges related to process scalability, stability, and cost-effectiveness.

2. Limited membrane permeability

While solubility determines how much drug is available for absorption, permeability dictates how efficiently the dissolved drug can traverse the gastrointestinal membrane to reach systemic circulation. Drugs with poor permeability (typically bcs class iii and iv) fail to diffuse through the lipid bilayer of enterocytes, leading to reduced bioavailability even when solubility is adequate.

Several molecular characteristics affect permeability, including **lipophilicity**, **molecular size**, **degree of ionization**, and **hydrogen bonding potential**. Excessive polarity or strong hydrogen bonding can restrict passive diffusion through the lipid-rich intestinal membrane. Furthermore, **biological transporters and enzymes** present in the intestinal epithelium play a decisive role. Efflux transporters like **p-glycoprotein (p-gp)** and **multidrug resistance-associated proteins (mrps)** can actively pump drugs back into the intestinal lumen, reducing

net absorption. Conversely, **influx transporters** such as **pept1** and **oatp** can facilitate the uptake of certain drugs and prodrugs.

Additionally, **paracellular transport** across tight junctions is highly limited for larger molecules, and permeability can also vary depending on the region of the gastrointestinal tract. Formulators often attempt to enhance permeability by using permeation enhancers, lipid carriers, or prodrug design; however, these methods must balance improved absorption with safety and mucosal integrity.

3. Gastrointestinal environment

The gastrointestinal (gi) tract presents a highly dynamic and complex environment that significantly influences drug solubility, stability, and absorption. Several physiological factors such as **ph variation**, **gastric emptying time**, **bile salt concentration**, **digestive enzymes**, and **microbial flora** affect the fate of orally administered drugs.

- **Ph variability:** the gi ph ranges from acidic (1–3) in the stomach to nearly neutral or slightly basic (6–8) in the small intestine. Drugs that are weak acids or bases may exhibit **ph-dependent solubility**, resulting in incomplete or variable dissolution. For instance, weakly basic drugs dissolve poorly in the intestine, while weak acids dissolve less in the stomach.
- **Enzymatic and chemical degradation:** acid-labile drugs such as omeprazole or erythromycin can degrade rapidly in the stomach, necessitating enteric-coated formulations. Similarly, peptides and proteins may be hydrolyzed by digestive enzymes, limiting their oral bioavailability.
- **First-pass metabolism:** drugs absorbed through the intestinal mucosa are often subjected to hepatic first-pass metabolism, which reduces the amount of active drug reaching systemic circulation.
- **Gastrointestinal motility:** variations in motility influence the residence time of the drug in absorption sites, thereby affecting dissolution and absorption kinetics.
- To mitigate these issues, formulators employ techniques such as enteric coating, ph-modifying excipients, enzyme inhibitors, and controlled-release systems that
  Optimize drug release in specific regions of the gi tract.

4. Formulation stability

Stability remains a cornerstone in the success of any oral formulation. It encompasses **chemical**, **physical**, and **microbiological** stability, ensuring that the drug maintains its potency, safety, and performance throughout its shelf life.

In many modern formulations — particularly those using **amorphous solid dispersions**, **nanoparticles**, or **lipid-based carriers** — maintaining stability poses a major challenge. Amorphous systems, though more soluble, are thermodynamically unstable and tend to recrystallize over time, leading to loss of solubility advantage. Similarly, nanosuspensions and emulsions can undergo **aggregation**, **phase separation**, or **oxidative degradation**, especially under stress conditions such as temperature or humidity fluctuations.

Chemical instability, such as **hydrolysis**, **oxidation**, or **photodegradation**, can further compromise the efficacy and safety of the formulation. Stabilization strategies include the incorporation of antioxidants, cryoprotectants, or polymeric stabilizers, as well as optimization of processing conditions and packaging. Ensuring long-term stability also involves rigorous stress testing and accelerated stability studies following **ich guidelines**.

In addition, achieving **scale-up compatibility** during manufacturing remains a concern. Techniques that are successful at laboratory scale, such as solvent evaporation or spray drying, may encounter reproducibility challenges during commercial production due to changes in heat and mass transfer dynamics.

Solubility enhancement strategies

The solubility of a drug substance plays a pivotal role in determining its dissolution rate, absorption, and overall bioavailability after oral administration. For a drug to be absorbed through the gastrointestinal membrane, it must first dissolve in the aqueous fluids of the gastrointestinal tract. Consequently, improving solubility is a primary objective in formulation design, particularly for biopharmaceutical classification system
(bcs) class ii and class iv drugs, which are characterized by low aqueous solubility.

Several technological and formulation-based approaches have been developed to enhance solubility and dissolution rate. These methods focus on modifying the **physicochemical properties of the drug**, **altering its solid-state characteristics**, or **optimizing the**

surrounding microenvironment to favor rapid dissolution. The following are the major and most widely applied strategies for solubility enhancement.

1. Particle size reduction

Particle size reduction is one of the simplest and most direct methods to enhance drug solubility and dissolution rate. According to the **noyes–whitney equation**, the rate of dissolution is directly proportional to the surface area of the solid exposed to the dissolution medium. By reducing particle size, the surface area increases, allowing greater interaction between the drug and solvent, thereby enhancing the dissolution rate.

Micronization and **nanosizing** are two common techniques employed for this purpose. Micronization can be achieved through **jet milling**, **ball milling**, or **spray drying**, which reduce particles to the micrometer range (1–10 μm). However, for drugs exhibiting extreme hydrophobicity, nanosizing may be more effective.

Nanosizing techniques such as **high-pressure homogenization**, **wet media milling**, or **precipitation methods** produce nanoparticles typically below 1000 nm. These nanoparticles not only increase dissolution rate but can also alter saturation solubility due to the increased surface curvature and gibbs–thomson effect. Furthermore, nanosuspensions can be stabilized using surfactants or polymers to prevent aggregation and improve redispersibility.

While size reduction methods are efficient, challenges such as particle aggregation, poor flow properties, and scalability must be carefully addressed during formulation development.

2. Solid dispersion technique

The **solid dispersion technique** is a powerful and widely used approach to enhance the dissolution and bioavailability of poorly water-soluble drugs. In this system, the drug is molecularly dispersed or finely distributed within a hydrophilic polymeric carrier matrix. Upon contact with aqueous media, the carrier dissolves rapidly, releasing the drug in an amorphous or molecularly dispersed form, thereby increasing surface area and wettability.

Commonly used carriers include **polyethylene glycol (peg)**, **polyvinylpyrrolidone (pvp)**, **hydroxypropyl methylcellulose (hpmc)**, and **poloxamers**. The key advantages of solid

Dispersions are:

- Conversion of the drug from crystalline to amorphous state, which has higher apparent solubility.
- Improved wettability and dissolution rate due to the hydrophilic nature of the carrier.
- Uniform dispersion of drug particles at molecular or colloidal levels.

Various preparation methods such as **fusion (melt) method**, **solvent evaporation**, **spray drying**, and **hot-melt extrusion** are used. Despite their advantages, solid dispersions may suffer from **physical instability** due to recrystallization of the amorphous drug during storage. Therefore, appropriate polymer selection and stabilization strategies are critical to maintaining the amorphous state.

3. Salt formation

Salt formation is one of the oldest and most effective techniques for enhancing the aqueous solubility of ionizable drugs. It involves converting a weak acid or base into its corresponding salt form, which exhibits altered ionization behavior and improved dissolution characteristics.

For instance, **weakly acidic drugs** such as diclofenac or naproxen are converted into **sodium or potassium salts**, while **weakly basic drugs** like metoprolol and propranolol are formulated as **hydrochloride or tartrate salts**. The salt form generally has greater solubility and dissolution rate due to the presence of ionic interactions with the
Solvent.

However, salt formation is only applicable to drugs that contain ionizable functional
Groups. Additionally, the selection of a counterion must consider **physiological compatibility**, **stability**, and **taste-masking requirements**. Certain salts may exhibit poor chemical stability, hygroscopicity, or undesirable pharmacokinetic alterations. Despite these limitations, salt formation remains a cost-effective and regulatory-accepted method for enhancing solubility.

4. Use of surfactants and co-solvents

Surfactants and **co-solvents** are valuable excipients used to improve the solubility of hydrophobic drugs by modifying the properties of the dissolution medium.

Surfactants lower the surface and interfacial tension between drug particles and solvent, thereby promoting wetting and dispersion. Above their **critical micelle**

Concentration (cmc), surfactants form micelles that solubilize hydrophobic drug molecules in their lipophilic core. Commonly used surfactants include **sodium lauryl sulfate (sls)**, **tween 80**, and **polysorbates**.

Co-solvents, on the other hand, enhance solubility by altering solvent polarity, allowing the drug to dissolve more easily in mixed solvent systems. Examples include

Ethanol, **propylene glycol**, **polyethylene glycol (peg-400)**, and **glycerin**.
While these agents can effectively increase solubility, they must be used within safe concentration limits to avoid toxicity, irritation, or precipitation upon dilution in gastrointestinal fluids. Moreover, their inclusion may influence drug stability, taste, and compatibility with packaging materials.

5. Inclusion complexation

Inclusion complexation is a molecular encapsulation strategy used to improve the solubility and stability of poorly soluble drugs. The most widely used host molecules for this purpose are **cyclodextrins**, cyclic oligosaccharides composed of α-1,4-linked
Glucose units that possess a hydrophilic outer surface and a lipophilic central cavity.
Hydrophobic drug molecules can fit into this central cavity, forming a **non-covalent inclusion complex** that enhances apparent solubility and dissolution rate. Among the various types, **β-cyclodextrin**, **hydroxypropyl-β-cyclodextrin (hp-β-cd)**, and **methylated derivatives** are frequently employed.

The advantages of this method include improved aqueous solubility, enhanced chemical stability, taste masking, and reduction in drug irritation. However, the major limitations are the **high cost** of cyclodextrins and the **limited complexation capacity** for large molecules. Despite these drawbacks, inclusion complexation remains a preferred method for improving the performance of hydrophobic drugs in oral formulations.

6. Amorphous systems

Drugs in the **amorphous state** possess higher thermodynamic activity, molecular mobility, and free energy compared to their crystalline counterparts, resulting in enhanced apparent solubility and faster dissolution rates. This increase occurs because amorphous solids lack a well-defined lattice structure, allowing easier disruption and solvation of molecules in aqueous media.

Amorphization can be achieved through various methods such as **rapid solvent evaporation**, **melt quenching**, **spray drying**, or **freeze drying**. Often, the amorphous drug is stabilized using polymers like **pvp**, **hpmc**, or **copovidone**, which inhibit molecular mobility and recrystallization.

However, amorphous systems are **thermodynamically unstable** and tend to revert to their crystalline form during storage, especially under high humidity or temperature. Therefore, the successful development of amorphous formulations requires careful optimization of formulation composition, moisture control, and packaging conditions.

Despite stability concerns, amorphous systems have demonstrated remarkable improvements in dissolution and bioavailability for several poorly soluble drugs such as itraconazole and indomethacin, making them an increasingly popular approach in modern formulation science.

Table 2: overview of common solubility and permeability enhancement techniques

Technique	Mechanism of action	Advantages	Limitations
Particle size reduction	Increases surface area for faster dissolution	Simple and effective	May cause aggregation
Solid dispersion	Drug dispersed in hydrophilic carrier	Improves wettability and dissolution	Physical instability
Salt formation	Alters ionization and ph-dependent solubility	Rapid dissolution	Limited to ionizable drugs
Co-solvency and	Modifies solvent polarity	Easy to formulate	Potential toxicity at

Technique	Mechanism of action	Advantages	Limitations
surfactants	and reduces interfacial tension		high levels
Cyclodextrin complexation	Forms inclusion complexes with hydrophobic drugs	Enhances solubility and stability	High cost and limited capacity
Lipid-based systems	Solubilize drugs in lipophilic vehicles	Improves absorption and lymphatic uptake	Requires stabilization and compatibility studies

Permeability enhancement strategies

1. Permeation enhancers

Agents such as bile salts, fatty acids, and surfactants can transiently alter membrane fluidity or tight junctions, enhancing paracellular transport.

2. Prodrug approach

Prodrugs are chemically modified derivatives that undergo enzymatic conversion into active drugs after absorption. Lipophilic prodrugs improve membrane permeation, while hydrophilic ones enhance solubility.

3. Lipid-based drug delivery systems (lbdds)

Lipid formulations such as self-emulsifying drug delivery systems (sedds) and solid lipid nanoparticles facilitate solubilization in the gastrointestinal tract and promote lymphatic uptake, bypassing first-pass metabolism.

4. Nanotechnology-based systems

Nanoparticles, liposomes, micelles, and dendrimers enhance permeability by protecting drugs from degradation and improving mucosal adhesion. These systems allow targeted delivery and controlled release.

5. Use of absorption modulators

Inhibitors of efflux transporters (e.g., verapamil for p-gp) can improve intracellular drug retention and enhance absorption. However, safety and regulatory concerns limit their use.

Role of biopharmaceutical modeling and in vitro testing

Modern formulation design relies on biopharmaceutical modeling tools to predict absorption kinetics. In vitro dissolution testing, permeability assays (caco-2 cell models), and computational simulations help anticipate in vivo behavior. The correlation between in vitro and in vivo performance (ivivc) is essential for regulatory approval and ensures consistent therapeutic outcomes.

Scope and future perspectives

Integration of nanotechnology and biopharmaceutics

Nanocarrier systems have revolutionized the field of oral drug delivery by enabling precise control over particle size, surface charge, and drug release kinetics. Future research aims to develop intelligent nanocarriers capable of responding to physiological triggers such as ph or enzymes.

Personalized medicine and predictive modeling

Advancements in computational biopharmaceutics and machine learning allow formulation scientists to predict solubility, permeability, and absorption profiles based on molecular descriptors. Personalized oral formulations based on patient-specific physiology may become a reality in the coming decade.

Emerging materials and hybrid systems

Hybrid lipid-polymer systems and bio-inspired carriers are being explored to synergistically enhance both solubility and permeability. Incorporating biocompatible and biodegradable excipients will further ensure safety and sustainability.

Regulatory and industrial perspectives

Regulatory agencies increasingly emphasize quality by design (qbd) and biopharmaceutics-based classification systems in product development. Integration of biopharmaceutical principles early in formulation design reduces development costs and improves success rates.

Conclusion

addressing biopharmaceutical limitations is crucial for successful oral drug therapy. By enhancing solubility, optimizing permeability, and ensuring stability, pharmaceutical researchers can significantly improve therapeutic outcomes. Techniques such as lipid-based carriers, solid dispersions, and prodrug modifications offer effective solutions for poorly soluble and poorly permeable drugs. Coupled with predictive modeling and bcs-based strategies, these approaches enable rational formulation design and reduced development risks. Regulatory compliance and quality assurance remain integral to translating laboratory findings into safe and effective medications. Ultimately, a comprehensive understanding of drug properties, formulation science, and patient-centric considerations is essential for developing oral drugs that are both effective and commercially viable, ensuring maximum therapeutic benefit and adherence.

References

1. Amidon, g. L., lennernäs, h., shah, v. P., & crison, j. R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *Pharmaceutical research, 12*(3), 413–420. Https://doi.org/10.1023/a:1016212804288
2. Dressman, j. B., reppas, c., & amidon, g. L. (2008). Understanding oral drug absorption: biopharmaceutical considerations in drug development. *European journal of pharmaceutical sciences, 33*(1), 1–5.
3. Löbenberg, r., & amidon, g. L. (2000). Modern bioavailability, bioequivalence, And biopharmaceutics classification system. *European journal of pharmaceutics and biopharmaceutics, 50*(1), 3–12.
4. Savjani, k. T., gajjar, a. K., & savjani, j. K. (2012). Drug solubility: importance and enhancement techniques. *Isrn pharmaceutics, 2012,* 195727. Https://doi.org/10.5402/2012/195727
5. Lipinski, c. A. (2002). Poor aqueous solubility—an industry wide problem in drug discovery. *American pharmaceutical review, 5*(3), 82–85.
6. Kawabata, y., wada, k., nakatani, m., yamada, s., & onoue, s. (2011). Formulation design for poorly water-soluble drugs based on biopharmaceutics classification

system: basic approaches and practical applications. *International journal of pharmaceutics, 420*(1), 1–10.

7. Kuentz, m., & holm, r. (2019). Lipid-based formulations for oral delivery of poorly soluble drugs. *Journal of pharmacy and pharmacology, 71*(9), 1400–1421.
8. Porter, c. J., trevaskis, n. L., & charman, w. N. (2007). Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. *Nature reviews drug discovery, 6*(3), 231–248.
9. Serajuddin, a. T. (1999). Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. *Journal of pharmaceutical sciences, 88*(10), 1058–1066.
10. Dahan, a., miller, j. M., & amidon, g. L. (2009). Prediction of solubility and permeability class membership: provisional bcs classification of the world's top oral drugs. *Aaps journal, 11*(4), 740–746.
11. Savla, r., browne, j., plassat, v., wasan, k. M., wasan, e. K., & johnston, t. P. (2017). Review and analysis of fda-approved drugs using lipid-based formulations. *Drug development and industrial pharmacy, 43*(11), 1743–1758.
12. Thakkar, h. P., & patel, b. V. (2020). Role of nanotechnology in enhancing solubility and permeability of poorly soluble drugs. *Asian journal of pharmaceutics, 14*(3), 312–321.